| S-1 based vs. cisplatin based therapy |
| Wu FL[14] |
Medicine (Baltimore) (2015) |
(Include S-1 -based vs. cisplatin-based therapy) |
Statistically similar. |
Objective RR: statistically similar. |
PFS: statistically similar. |
NA. |
- |
| S-1 based combination therapy vs. S-1 monotherapy |
| Ter Veer E[7] |
Gastric Cancer (2016) |
(Include S-1-based combination therapy vs. S-1 monotherapy) |
Favor S-1 combination therapy. |
Objective RR: favor S-1 combination therapy. |
PFS: favor S-1 combination therapy. |
AEs: higher in S-1 combination therapy. |
S-1 combination therapy was more efficacious than S-1 monotherapy. |
| Liu GF[20] |
World J Gastroenterol (2014) |
S-1-based combination therapy vs. S-1 monotherapy |
Favor S-1 combination therapy. |
Overall RR: favor S-1 combination therapy. |
PFS: favor S-1 combination therapy. |
Grade 3-4 leucopenia, neutropenia, diarrhea: higher in S-1 combination therapy. |
S-1-based combination therapy was superior to monotherapy in terms of OS, PFS and overall RR. |
| Wu JR[23] |
Tumour Biol (2014) |
S-1-based combination therapy vs. S-1 monotherapy. |
Favor S-1 combination therapy. |
Objective RR: favor S-1 combination therapy. |
PFS: favor S-1 combination therapy. |
Grade 3/4 toxicity event: higher in S-1 combination therapy. |
For the Asian population, S-1 combination therapy improved OS and PFS and enhanced objective RR. The safety profile was poorer in patients with S-1 combination therapy |
